Dan Schmitt
President and CEO, Actuate Therapeutics, Inc.
Grayslake, Illinois, United States
Professional Overview
Dan Schmitt is an accomplished pharmaceutical executive with over 30 years of experience driving innovation and growth in the healthcare industry. As the President and CEO of Actuate Therapeutics, Inc., he leverages his deep expertise in new product development, licensing, and commercial strategy to advance the company's pipeline of novel oncology therapies.
Experience Summary
Current Role
As President and CEO of Actuate Therapeutics, Inc. since 2015, Dan is responsible for setting the strategic vision, leading the executive team, and overseeing the company's research and development efforts. Under his leadership, Actuate has advanced multiple drug candidates into clinical trials, forged key industry partnerships, and secured significant funding to support its growth.
Career Progression
Prior to joining Actuate, Dan held several senior-level roles, including Chief Operating Officer at Genus Oncology LLC, Senior Vice President of Licensing and Commercial Development at Immtech Pharmaceuticals Inc., and various leadership positions at Searle/Pharmacia and Fujisawa. Throughout his career, he has demonstrated a track record of success in new product planning, commercial strategy, and business development, helping to bring innovative therapies to market.
Academic Background
Dan holds a Bachelor of Science degree in Biology from the University of Illinois at Urbana-Champaign, where he graduated with honors.
Areas of Expertise
- Oncology drug development
- Pharmaceutical licensing and commercialization
- Strategic business planning and execution
- Cross-functional team leadership
- Regulatory and clinical trial management
Professional Impact
Under Dan's leadership, Actuate Therapeutics has advanced multiple novel oncology drug candidates into clinical trials, established partnerships with leading academic institutions and pharmaceutical companies, and secured over $100 million in funding to support its research and development efforts. His industry expertise and strategic vision have positioned the company as a leader in the development of innovative cancer treatments.
Conclusion
With his extensive experience in the pharmaceutical industry and a proven track record of driving innovation and growth, Dan Schmitt is a valuable asset to Actuate Therapeutics. As the company continues to expand its pipeline and reach new milestones, Dan's strategic leadership and deep industry knowledge will be instrumental in advancing the company's mission to develop transformative cancer therapies.
